Logan Roof is an Oncology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 45 publications with 269 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 W 10th Ave Fl 2
Columbus, OH 432101280
Telephone
614-293-5066Provider last certified this registry record 26 Feb 2026.
Clinical trials
- A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20252 payments
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
43.9%Phenothiazine43.9%Prochlorperazine Maleate100%Part D≥16 patientsCancer & immunology
29.8%Kinase inhibitor29.8%Tagrisso100%Part D<11 patientsSensory organs
26.3%Corticosteroid26.3%Dexamethasone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
Journal of Clinical Oncology
2026 - Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
Journal of Clinical Oncology
2026 - Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
Journal of Clinical Oncology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Colleen Cebulla, MD
The Ohio State University Wexner Medical Center
Michael Grever, MD
The Ohio State University Wexner Medical Center
Brad Rovin, MD
The Ohio State University Wexner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”